C12N 2710/10042
Virus or viral particle as vehicle
Official title: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
C12N2710/10042 (Virus or viral particle as vehicle) appears on 27 US grants and 42 published applications in this corpus.
Search patents in C12N- Granted patents
- 27
- Published applications
- 42
- Assignees
- 29
- Inventors
- 80
- Latest grant
- 16 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 2 |
| 2015 | 1 | 10 |
| 2016 | 3 | 2 |
| 2017 | 4 | 4 |
| 2018 | 3 | 3 |
| 2019 | 1 | 4 |
| 2020 | 5 | 3 |
| 2021 | 2 | 3 |
| 2022 | 2 | 4 |
| 2023 | 1 | 1 |
| 2024 | 4 | 2 |
| 2025 | 1 | 0 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Engineering virus-like nanocarriers for biomolecule delivery16 Sep 2025US 12,415,837 B2University of Utah Research Foundation
- Hepatocyte based insulin gene therapy for diabetes10 Dec 2024US 12,163,147 B2Wisconsin Alumni Research Foundation
- PH-sensitive and bioreducible polymer-virus complex for cancer treatment30 Apr 2024US 11,970,715 B2Genemedicine Co., Ltd.
- Adeno-associated virus compositions for restoring F8 gene function and methods of use thereof6 Feb 2024US 11,891,619 B2City of Hope
- Simian adenovirus and hybrid adenoviral vectors2 Jan 2024US 11,857,640 B2Oxford University Innovation Limited
- Tet-r expression cassettes and cell lines16 Jul 2026US 2026/0201417 A1Cevec Pharmaceuticals GmbH
- Hepatocyte Based Insulin Gene Therapy for Diabetes30 Apr 2026US 2026/0117250 A1Wisconsin Alumni Research Foundation
- Modification of epor-encoding nucleic acids7 Nov 2024US 2024/0368582 A1Ensoma, Inc.
- Simian Adenovirus and Hybrid Adenoviral Vectors6 Jun 2024US 2024/0181078 A1Oxford University Innovation Limited
- Modified adenoviruses for infectious disease vaccine development2 Mar 2023US 2023/0062122 A1
Most cited
By later US patents
- Simian adenovirus and hybrid adenoviral vectors21US 9,714,435 B2Oxford University Innovation Limited · 2017
- Recombinant adenoviruses and use thereof13US 10,781,427 B2Beth Israel Deaconess Medical Center, Inc. · 2020
- Adenoviral vectors for transduction of vascular tissue8US 9,476,061 B2Janssen Vaccines & Prevention B. V. · 2016
- Recombinant adenoviruses and use thereof5US 10,106,781 B2Beth Israel Deaconess Medical Center, Inc. · 2018
- Hepatocyte based insulin gene therapy for diabetes4US 9,732,356 B2Wisconsin Alumni Research Foundation · 2017